nach oben

Erschienen in:

24.05.2019 | Preclinical study

Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study

verfasst von: Marta Pineda-Moncusí, Sonia Servitja, Ignasi Tusquets, Adolfo Diez-Perez, Albora Rial, Maria Lourdes Cos, Isabel Campodarve, Jaime Rodriguez-Morera, Natalia Garcia-Giralt, Xavier Nogués

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The most frequent adverse effects of aromatase inhibitors (AI) are arthralgia and bone loss induction. These reduce the quality of life of patients and their adherence to the treatment. This study evaluates the early AI cessation caused by AI intolerance, and the evolution of joint pain and health-related quality of life (HRQoL) during AI treatment until 1-year after AI completion.

Methods

Data of 910 women diagnosed with early breast cancer and candidates for AI were recruited in B-ABLE cohort. AI discontinuation was analyzed by survival analysis, including Kaplan–Meier estimation and Cox regression. Patients were distributed in three groups of the study according to previous tamoxifen (TAM) exposure and length of AI treatment: TAM-2yAI, TAM-3yAI, and 5yAI. Evolution of joint pain and HRQoL in osteoporosis was evaluated using Visual Analog Scale (VAS) and ECOS-16 tests, respectively, from baseline to 1-year after AI completion through repeated-measures ANOVA.

Results

Risk of AI discontinuation was increased in patients previously exposed to tamoxifen compared to non-exposed (adjusted HR 5.30 [95% CI 2.23 to 12.57]). VAS and ECOS-16 scores of TAM-2yAI and TAM-3yAI groups increased during AI treatment, mainly during the first 3–12 months. After 1-year from AI completion, values tend to decrease to baseline levels. In 5yAI group, VAS and ECOS-16 levels increased at three months, and VAS remained significantly higher at 1-year post-treatment.

Conclusions

AI therapy increased joint pain and reduced HRQoL, mainly during the first year of treatment. Patients previously treated with tamoxifen experienced greater pain when they switched to AI therapy and had an excess risk of discontinuation during the first 12 months.

Trial registration

ClinicalTrials.gov: NCT03811509. Registered 28 January 2018-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03811509.

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ (2018) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. https://doi.org/10.1200/JCO.18.01160 CrossRefPubMed

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, Investigators AL (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135–1141. https://doi.org/10.1016/S1470-2045(10)70257-6 CrossRefPubMed

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Lang I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thurlimann B, Group BIGC, International Breast Cancer Study G (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12(12):1101–1108. https://doi.org/10.1016/S1470-2045(11)70270-4 CrossRefPubMedPubMedCentral

Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL (2016) Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. Oncologist 21(5):539–546. https://doi.org/10.1634/theoncologist.2015-0349 CrossRefPubMedPubMedCentral

Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26(7):1051–1057. https://doi.org/10.1200/JCO.2007.11.0726 CrossRefPubMed

Laroche F, Coste J, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Decleves X, de Cremoux P, Bouhassira D, Perrot S (2014) Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. J Pain 15(3):293–303. https://doi.org/10.1016/j.jpain.2013.11.004 CrossRefPubMed

Pineda-Moncusi M, Servitja S, Casamayor G, Cos ML, Rial A, Rodriguez-Morera J, Tusquets I, Diez-Perez A, Garcia-Giralt N, Nogues X (2018) Bone health evaluation one year after aromatase inhibitors completion. Bone 117:54–59. https://doi.org/10.1016/j.bone.2018.09.010 CrossRefPubMed

Niravath P (2013) Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 24(6):1443–1449. https://doi.org/10.1093/annonc/mdt037 CrossRefPubMed

Goldvaser H, Barnes TA, Seruga B, Cescon DW, Ocana A, Ribnikar D, Amir E (2018) Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx141 CrossRefPubMed

10.

Rizzoli R (2018) Postmenopausal osteoporosis: assessment and management. Best Pract Res Clin Endocrinol Metab 32(5):739–757. https://doi.org/10.1016/j.beem.2018.09.005 CrossRefPubMed

11.

Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP (2011) Validity of four pain intensity rating scales. Pain 152(10):2399–2404. https://doi.org/10.1016/j.pain.2011.07.005 CrossRefPubMed

12.

Badia X, Diez-Perez A, Lahoz R, Lizan L, Nogues X, Iborra J (2004) The ECOS-16 questionnaire for the evaluation of health related quality of life in post-menopausal women with osteoporosis. Health Qual Life Outcomes 2:41. https://doi.org/10.1186/1477-7525-2-41 CrossRefPubMedPubMedCentral

13.

Hawker GA, Mian S, Kendzerska T, French M (2011) Measures of adult pain: visual analog scale for pain (VAS Pain), numeric rating scale for pain (NRS Pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). Arthritis Care Res (Hoboken) 63(Suppl 11):S240–252. https://doi.org/10.1002/acr.20543 CrossRef

14.

Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez-Garcia M, Diez-Perez A, Albanell J, Tusquets I, Nogues X (2011) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 125(3):869–878. https://doi.org/10.1007/s10549-010-1075-9 CrossRefPubMed

15.

Garcia-Giralt N, Rodriguez-Sanz M, Prieto-Alhambra D, Servitja S, Torres-Del Pliego E, Balcells S, Albanell J, Grinberg D, Diez-Perez A, Tusquets I, Nogues X (2013) Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. Breast Cancer Res Treat 140(2):385–395. https://doi.org/10.1007/s10549-013-2638-3 CrossRefPubMed

16.

ClinicalTrials.gov (2019) Study for improving life quality in breast cancer women treated with aromatase inhibitors: cohort B-ABLE. Parc de Salut Mar, Instituto de Salud Carlos III, Hospital del Mar, Barcelona

17.

Rodriguez-Sanz M, Prieto-Alhambra D, Servitja S, Garcia-Giralt N, Garrigos L, Rodriguez-Morera J, Albanell J, Martinez-Garcia M, Gonzalez I, Diez-Perez A, Tusquets I, Nogues X (2016) AI-related BMD variation in actual practice conditions: a prospective cohort study. Endocr Relat Cancer 23(4):303–312. https://doi.org/10.1530/ERC-16-0025 CrossRefPubMed

18.

Servitja S, Nogues X, Prieto-Alhambra D, Martinez-Garcia M, Garrigos L, Pena MJ, de Ramon M, Diez-Perez A, Albanell J, Tusquets I (2012) Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. Breast 21(1):95–101. https://doi.org/10.1016/j.breast.2011.09.001 CrossRefPubMed

19.

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23(3):619–629. https://doi.org/10.1200/JCO.2005.09.121 CrossRefPubMed

20.

Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936–942. https://doi.org/10.1200/JCO.2011.38.0261 CrossRefPubMedPubMedCentral

21.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V (2018) A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-018-4811-1 CrossRefPubMed

22.

Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101(23):1624–1632. https://doi.org/10.1093/jnci/djp386 CrossRefPubMedPubMedCentral

23.

Wang J, Tang X, Shen Y, Shang G, Fang L, Wang R, Xu Y (2015) The correlations between health-related quality of life changes and pain and anxiety in orthodontic patients in the initial stage of treatment. Biomed Res Int 2015:725913. https://doi.org/10.1155/2015/725913 CrossRefPubMedPubMedCentral

24.

Kawai K, Kawai AT, Wollan P, Yawn BP (2017) Adverse impacts of chronic pain on health-related quality of life, work productivity, depression and anxiety in a community-based study. Fam Pract 34(6):656–661. https://doi.org/10.1093/fampra/cmx034 CrossRefPubMedPubMedCentral

Titel: Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study
verfasst von: Marta Pineda-Moncusí
Sonia Servitja
Ignasi Tusquets
Adolfo Diez-Perez
Albora Rial
Maria Lourdes Cos
Isabel Campodarve
Jaime Rodriguez-Morera
Natalia Garcia-Giralt
Xavier Nogués
Publikationsdatum: 24.05.2019
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05289-7

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study

Abstract

Purpose

Methods

Results

Conclusions

Trial registration

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Trial registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Yoga has a solid effect on cancer-related fatigue in patients with breast cancer: a meta-analysis

The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay

Is sentinel node biopsy necessary in the radiologically negative axilla in breast cancer?

Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

Is immediate breast reconstruction safe in women over 70? An analysis of the National Surgical Quality Improvement Program (NSQIP) database

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie